RxDoctor Payments Data

Richard Smith, MD

Family Medicine · College Station, TXNPI 1730270182

Payments from drug & device makers

$4,346in general payments, 2019–2025

Across 95 payments — averaging $45.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Novo Nordisk$1K
  • AstraZeneca$698
  • Pfizer$336
  • Amgen$183
  • Idorsia Pharmaceuticals US Inc$155
  • plus $628 from 11 others

What the payments were for

  • Consulting fees$1,20028%
  • Food & beverage$3,12072%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,346 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$148,743
Medicare patients
377
Services billed
2,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin262$226,806
TrulicityDulaglutide144$197,801
OzempicSemaglutide132$139,486
MounjaroTirzepatide102$120,126
EliquisApixaban119$90,560
ProliaDenosumab17$28,039
JanuviaSitagliptin Phosphate28$27,861
RybelsusSemaglutide19$20,139
XareltoRivaroxaban21$16,852
FarxigaDapagliflozin Propanediol18$16,688
Tresiba Flextouch U-200Insulin Degludec16$16,508
SymbicortBudesonide/Formoterol Fumarate23$14,793
Repatha SureclickEvolocumab16$8,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,142
PremarinEstrogens, Conjugated21$7,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$135$317,927246 claims
Boehringer IngelheimJardiance$33$226,806262 claims
Novo NordiskOzempic, Rybelsus$1,008$159,624151 claims
PfizerEliquis, Premarin$336$98,045140 claims
AstraZenecaFarxiga, Symbicort$698$31,48141 claims
AmgenProlia$183$28,03917 claims
MerckJanuvia$33$27,86128 claims
AbbVieSynthroid$12$4,51984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in College Station

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →